Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
2.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

3.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

4.

Targeting the androgen receptor.

Friedlander TW, Ryan CJ.

Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Review.

PMID:
23084523
5.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558
6.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

7.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
8.

Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.

Pal SK, Twardowski P, Josephson DY.

Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Review.

PMID:
19733987
9.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

10.

Targeting extra-gonadal androgens in castration-resistant prostate cancer.

Grist E, de Bono JS, Attard G.

J Steroid Biochem Mol Biol. 2015 Jan;145:157-63. doi: 10.1016/j.jsbmb.2014.09.006. Epub 2014 Sep 22. Review.

PMID:
25251387
11.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
12.

Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.

Graham L, Schweizer MT.

Med Oncol. 2016 May;33(5):44. doi: 10.1007/s12032-016-0759-3. Epub 2016 Apr 4. Review.

PMID:
27042852
13.

Prostate cancer-from steroid transformations to clinical translation.

Chang KH, Sharifi N.

Nat Rev Urol. 2012 Dec;9(12):721-4. doi: 10.1038/nrurol.2012.175. Epub 2012 Oct 2. Review.

PMID:
23027067
14.

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.

Kim W, Ryan CJ.

Curr Treat Options Oncol. 2012 Jun;13(2):189-200. doi: 10.1007/s11864-012-0188-2. Review.

PMID:
22539224
15.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851
16.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

17.

Abiraterone in prostate cancer: a new angle to an old problem.

Stein MN, Goodin S, Dipaola RS.

Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Review.

18.

[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].

Brasso K, Thomsen FB, Berg KD, Røder MA, Iversen P.

Ugeskr Laeger. 2013 Sep 30;175(40):2328-32. Review. Danish.

PMID:
24079321
20.

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Zhang T, Zhu J, George DJ, Armstrong AJ.

Expert Opin Pharmacother. 2015 Mar;16(4):473-85. doi: 10.1517/14656566.2015.995090. Epub 2014 Dec 23. Review.

PMID:
25534660

Supplemental Content

Support Center